Linezolid

Generic Name: Linezolid

Brand Names: Zyvox, Zyvoxam

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₀FN_₃O_₄

CAS Number: 165800-03-3

Unique Ingredient Identifier: ISQ9I6J12J

Background: Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...

Indication: Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...

Associated Conditions: Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection

Associated Therapies: -

Clinical Trials

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Linezolid
Drug: Tedizolid phosphate

First Posted Date: 2013-12-24

Last Posted Date: 2019-06-27

Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 726

Registration Number: NCT02019420

Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis

Phase 2

Conditions: Pulmonary Tuberculosis Without Resistance to Rifampicin

Interventions: Drug: Linezolid
Drug: Ethambutol

First Posted Date: 2013-11-25

Last Posted Date: 2014-12-30

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 429

Registration Number: NCT01994460

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Kyunggi, Korea, Republic of
🇰🇷
National Medical Center, Seoul, Korea, Republic of
🇰🇷
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Phase 3

Completed

Conditions: Skin Diseases, Infectious

Interventions: Drug: Tedizolid Phosphate (Sivextro, BAY1192631)
Drug: Linezolid

First Posted Date: 2013-10-22

Last Posted Date: 2018-10-04

Lead Sponsor: Bayer

Target Recruit Count: 125

Registration Number: NCT01967225

Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia

Phase 4

Completed

Conditions: Pneumonia

Interventions: Drug: Linezolid

First Posted Date: 2013-03-06

Last Posted Date: 2021-12-01

Lead Sponsor: University Ghent

Target Recruit Count: 15

Registration Number: NCT01805284

Locations: 🇧🇪
Ghent University Hospital, Ghent, Belgium

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Phase 3

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Drug: Trimethoprim-Sulfamethoxazole
Drug: Flucloxacillin
Drug: Clindamycin
Drug: Cloxacillin
Drug: Linezolid
Drug: Vancomycin
Drug: Daptomycin
Drug: Cefazolin

First Posted Date: 2013-02-15

Last Posted Date: 2020-05-27

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 215

Registration Number: NCT01792804

Locations: 🇳🇱
Amsterdam, Amsterdam, Netherlands
🇳🇱
Tilburg, Tilburg, Netherlands
🇳🇱
Diakonessenhuis Utrecht, Utrecht, Netherlands

and more 37 locations

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection

Phase 2

Conditions: Hip Prosthetic Joint Infection

Interventions: Drug: VANCOMYCIN
Drug: CEFTRIAXONE
Drug: LINEZOLID
Drug: CLINDAMYCIN
Drug: SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)
Drug: FLUOROQUINOLONE
Drug: RIFAMPIN

First Posted Date: 2012-12-28

Last Posted Date: 2014-05-28

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 100

Registration Number: NCT01757236

Locations: 🇫🇷
CHRU de Tours, Tours, Indre et Loire, France
🇮🇹
Azienda Opedaliera Universitaria San Maria della Misericordia, Udine, Italy
🇫🇷
CHU de Nantes, Nantes, France

and more 6 locations